Skip to main content

Table 2 Factors associated with poor-compliance in subjects of total cohort and subgroup

From: Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review

 

Total subjects at year 1 (n = 333)

Subgroup subjects at year 2 (n = 174)a

Risk factors

n (%)

Univariate analysis

Multivariate analysis

n (%)

Univariate analysis

Multivariate analysis

 

OR 95% CI

p-value

OR 95% CI

p-value

 

OR 95% CI

p-value

OR 95% CI

p-value

Age

 

1.03 (1.01-1.05)

0.007

1.02 (0.99-1.05)

0.132

 

0.97 (0.94-0.99)

0.045

0.97 (0.94-1.01)

0.100

First prescribed by

          

 Rheumatologist

55 (34.6)

1.0 (referent)

 

1.0 (referent)

 

24 (48.0)

1.0 (referent)

 

1.0 (referent)

 Orthopedist

64 (40.3)

2.67 (1.58-4.53)

0.000

2.30 (1.26-4.22)

0.007

13 (26.0)

1.38 (0.60-3.14)

0.447

1.52 (0.58-3.96)

0.394

 Others

40 (25.2)

1.19 (0.70-2.03)

0.525

1.12 (0.62-2.05)

0.709

13 (26.0)

0.85 (0.39-1.86)

0.679

0.86 (0.35-2.14)

0.746

DXA

13 (8.2)

0.52 (0.32-0.85)

0.008

0.51 (0.28-0.93)

0.029

17 (34.0)

0.97 (0.49-1.94)

0.932

0.94 (0.39-2.26)

0.895

Vertebroplasty

5 (3.1)

0.91 (0.27-3.04)

0.877

0.59 (0.15-2.30)

0.450

1 (2.0)

0.49 (0.06-4.27)

0.515

0.71 (0.07-7.08)

0.769

Fracture site

          

 Spine fracture

131 (82.4)

1.40 (0.81-2.40)

0.225

1.54 (0.45-5.29)

0.489

36 (72.0)

0.68 (0.32-1.45)

0.320

0.37 (0.05-2.95)

0.345

 Hip fracture

27 (17.0)

1.49 (0.81-2.76)

0.204

1.21 (0.41-3.54)

0.731

7 (14.0)

1.28 (0.48-3.36)

0.620

0.47 (0.06-3.50)

0.457

 Others fracture

13 (8.2)

1.85 (0.75-4.58)

0.185

1.88 (0.69-5.10)

0.216

3 (6.0)

1.52 (0.35-6.61)

0.577

1.16 (0.22-6.23)

0.863

Tobacco useb

1 (0.6)

--

0.477

0.00 (0.00)

1.000

0 (0)

--

--

--

--

Alcohol use

1 (0.6)

1.10 (0.07-17.65)

0.949

0.00 (0.00)

1.000

1 (2.0)

4.09 (0.00)

1.000

1.37 (0.00)

1.000

Malignancy

11 (6.9)

1.00 (0.43-2.34)

0.994

0.98 (0.39-2.45)

0.960

3 (6.0)

0.82 (0.21-3.15)

0.767

0.78 (0.19-3.27)

0.734

Cardiac disease

32 (20.1)

1.94 (1.06-3.56)

0.032

1.87 (0.93-3.75)

0.079

7 (14.0)

1.39 (0.52-3.72)

0.512

1.79 (0.58-5.49)

0.311

Respiratory disease

19 (11.9)

1.34 (0.66-2.71)

0.413

1.22 (0.57-2.63)

0.610

4 (8.0)

0.81 (0.25-2.65)

0.729

0.72 (0.20-2.56)

0.611

Neuropsychiatric disease

30 (18.9)

1.21 (0.69-2.14)

0.505

0.89 (0.47-1.70)

0.732

6 (12.0)

0.63 (0.24-1.67)

0.354

0.68 (0.23-2.02)

0.485

Chronic kidney disease

12 (7.5)

1.34 (0.56-3.19)

0.509

1.35 (0.51-3.58)

0.548

2 (4.0)

0.60 (0.12-2.95)

0.533

0.66 (0.12-3.62)

0.636

Endocrine/metabolic

29 (18.2)

1.54 (0.85-2.81)

0.157

1.81 (0.90-3.64)

0.095

6 (12.0)

0.92 (0.34-2.51)

0.871

0.82 (0.26-2.60)

0.734

Hypertension

49 (30.8)

0.83 (0.52-1.31)

0.411

0.62 (0.37-1.06)

0.083

21 (42.0)

1.52 (0.77-2.99)

0.224

1.62 (0.77-3.43)

0.207

Rheumatoid arthritis

3 (1.9)

0.22 (0.06-0.78)

0.011

0.19 (0.04-0.81)

0.025

4 (8.0)

0.99 (0.30-3.32)

0.989

0.81 (0.17-3.89)

0.790

Hepatobiliary disease

6 (3.8)

0.42 (0.16-1.10)

0.075

0.44 (0.16-1.25)

0.124

2 (4.0)

0.36 (0.08-1.64)

0.185

0.45 (0.09-2.33)

0.340

Steroid use

21 (13.2)

0.73 (0.40-1.34)

0.307

1.48 (0.68-3.22)

0.320

10 (20.0)

1.30 (0.56-3.02)

0.541

1.02 (0.31-3.29)

0.980

  1. OR odds ratio, CI confidence interval, Serum creatinine >1.4 mg/dl; aSubjects with MPR ≥ 80% at year 1; bNo one smoked, so the factor cannot be estimated; All comparisons denote present vs. absent.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us